Prenetics Global (PRE) Insider Cheng Yin Pan Sells 15,873 Shares

Cheng Yin Pan sold 15,873 shares of Prenetics Global Limited (PRE) on June 15, 2026. This transaction was part of a series of internal moves involving the same insider, who also reported two separate acquisitions of 15,873 shares on that same day. The stock trades on the NasdaqGM and is currently in focus as the company prepares for its next financial update later this year.

Insider Buying and Selling at Prenetics Global Limited

The sale by Cheng Yin Pan was one of several filings disclosed for June 15, 2026. Along with the sale, Pan acquired two blocks of 15,873 shares each. Another insider, David Vanderveen, was also active on the same date, selling 8,681 shares and buying 6,944 shares. None of these transactions were conducted under a Rule 10b5-1 plan, which is a pre-scheduled trading arrangement often used to avoid potential conflicts of interest. The filings did not disclose specific dollar values for the transactions.

Prenetics Global Stock Performance

On Tuesday, shares of Prenetics Global were priced at $20.75. The stock has stayed well above its 52-week low of $11.36 but remains below the 52-week peak of $27.24. With a beta of 0.309, the stock typically moves less sharply than the broader market. It is currently trading near its 50-day moving average of $21.34 and holds a market value of roughly $408.41 million.

Recent Earnings and Financial Health

Prenetics Global reported revenue of $154.59 million in its most recent filing, with revenue growing at 2.1%. The company is not currently profitable, reporting a loss of $3.46 per share and a net margin of negative 30.4%. Its return on equity also stands at negative 47%. Despite these losses, the company maintains a quick ratio of 3.657, suggesting it has enough liquid assets to cover its short-term liabilities. Investors are looking toward November 10, 2026, for the company's next earnings report.

Analysts Set New Price Targets

Wall Street firms have recently shown increased interest in the health sciences company. On October 12, 2026, Lucid Capital Markets initiated coverage on the stock with a Buy rating and set a price target of $54.00. This followed an initiation by Craig-Hallum on September 17, 2026, which also assigned a Buy rating and a $40.00 target. B. Riley Securities started its coverage on August 27, 2026, with a Buy rating and a $37.00 price target. Earlier, on July 15, 2026, Benchmark maintained its Buy rating while raising its price target from $30.00 to $40.00. The consensus among seven analysts is a strong buy, with a mean price target of $35.86.

About Prenetics Global Limited

Prenetics Global operates as a consumer health sciences firm. It focuses on longevity and preventative health products under its IM8 brand and provides personalized genetic reports through its CircleDNA technology. Based in Hong Kong, the company uses DNA sequencing to help people understand their health risks and nutritional needs.

What's Ahead for PRE

The recent insider sales and buys provide a snapshot of internal activity as the company heads into the second half of the year. While these transactions were disclosed in June, investors should remember that insider reports are backward-looking and may not reflect current sentiment or future performance. The next major catalyst for the stock is likely to be the earnings announcement scheduled for November.